GLP-1 Nurse Practitioner vs Doctor Telehealth: Which Should You Choose? (2026 Guide)
By WPG Research Team · Published · Last verified:
General health information, not personal medical advice. We may earn affiliate commissions from some telehealth providers linked on this page. That does not change our verification criteria.
Short answer: Less than you'd think, and not in the way you're worried about. Nurse practitioners can legally prescribe FDA-approved GLP-1 medications — Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Rybelsus, Foundayo — in all 50 states when licensed in your state, practicing within their NP scope, and following that state's collaboration or supervision rules.
The bigger questions: Is your prescriber licensed in your state? Do they screen for contraindications? Is the medication FDA-approved or compounded? Are they monitoring you over time? Here's how to answer all of them in 10 minutes before you pay.
GLP-1 NP vs Doctor Telehealth: Quick-Fit Table
| Your situation | Better first choice | Why |
|---|---|---|
| Healthy adult, BMI 30+ (or 27+ with one weight-related condition), no major medication issues | Licensed NP or doctor telehealth — either fine | Credential matters less than screening, labs, and follow-up |
| You take insulin or sulfonylureas for type 2 diabetes | Doctor, endocrinologist, or PCP-coordinated care | Hypoglycemia risk needs closer monitoring |
| You have diabetic retinopathy | Doctor or endocrinology-connected program | Rapid blood-sugar improvement can temporarily worsen retinopathy |
| History of pancreatitis, gallbladder disease, severe GI disease, or gastroparesis | Doctor or obesity medicine specialist | Risk review and escalation needed |
| Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 | Do not start a GLP-1 — talk to a specialist | This is a boxed-warning contraindication on Wegovy, Zepbound, and Foundayo labels |
| Pregnant, breastfeeding, or planning pregnancy soon | Do not start without OB/PCP guidance | Pregnancy guidance is medication-specific; Foundayo may reduce oral contraceptive effectiveness |
| You've previously had severe side effects on a GLP-1 | Board-certified obesity medicine physician | Needs nuanced re-evaluation |
| Mainly worried about insurance and prior authorization | PCP, or a telehealth program with documented PA support | Coverage depends on plan rules, not credential |
| You can't get an appointment with your PCP for months | NP-led or doctor-led telehealth with strong screening | Access matters; verify the program before paying |
Why "NP vs Doctor" Is the Wrong First Question
Quick answer
People assume "doctor = safer." It feels intuitive — doctors train longer (about 11–15 years after high school) than nurse practitioners (about 6–8 years). But not in the way that matters for a routine GLP-1 prescription. The decisions that actually affect your safety:
Can a Nurse Practitioner Prescribe GLP-1 Medications Through Telehealth?
Quick answer
- Full Practice Authority: NP can evaluate, diagnose, order labs, manage treatment, and write your prescription on their own license — no physician co-signature required.
- Reduced Practice: State law requires a career-long regulated collaborative agreement with another health provider for the NP to provide patient care.
- Restricted Practice: A physician must supervise, delegate, or co-manage at least one element of NP practice on a career-long basis.
Which GLP-1 Medications NPs Can Prescribe
Every FDA-approved GLP-1 for weight management or type 2 diabetes can be prescribed by an NP within state rules. As of May 2026:
| Brand name | Active ingredient | Form | FDA-approved use |
|---|---|---|---|
| Wegovy | semaglutide | Weekly injection + once-daily oral tablet | Chronic weight management; cardiovascular risk reduction in adults with established CVD and obesity/overweight; noncirrhotic MASH with moderate to advanced liver fibrosis (accelerated approval) |
| Ozempic | semaglutide | Weekly injection | Type 2 diabetes (used off-label for weight loss) |
| Rybelsus | semaglutide | Daily oral tablet | Type 2 diabetes |
| Zepbound | tirzepatide | Weekly injection | Chronic weight management; moderate-to-severe obstructive sleep apnea in adults with obesity |
| Mounjaro | tirzepatide | Weekly injection | Type 2 diabetes (used off-label for weight loss) |
| Saxenda | liraglutide | Daily injection | Chronic weight management (adults and adolescents 12+) |
| Foundayo | orforglipron | Daily oral tablet (no food/water restrictions) | Chronic weight management; FDA-approved April 1, 2026 |
Mississippi off-label rule — the state-specific detail most articles skip
What State Rules Decide Whether GLP-1 Telehealth Is Legal?
Quick answer
As of the AANP State Practice Environment map dated May 2026, 28 states plus Washington D.C. give nurse practitioners Full Practice Authority. 11 states fall under Reduced Practice. 11 states fall under Restricted Practice.
Full Practice Authority — 28 states + D.C.
Alaska · Arizona · Colorado · Connecticut · Delaware · Hawaii · Idaho · Iowa · Kansas · Maine · Maryland · Massachusetts · Minnesota · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Dakota · Oregon · Rhode Island · South Dakota · Utah · Vermont · Washington · Wyoming · Washington, D.C.
New Jersey transitioned to full practice authority following 2026 state legislation signed by Governor Sherrill. Several states — NY, CT, MA, CO and others — require NPs to complete a transition-to-practice period of supervised hours before independent practice kicks in.
Reduced Practice — 11 states (career-long collaborative agreement required)
Alabama · Arkansas · Illinois · Indiana · Kentucky · Louisiana · Mississippi · Ohio · Pennsylvania · West Virginia · Wisconsin
Restricted Practice — 11 states (physician supervision required)
California · Florida · Georgia · Michigan · Missouri · North Carolina · Oklahoma · South Carolina · Tennessee · Texas · Virginia
What This Actually Means When You Click "Start Now"
| If you live in a… | What's happening behind the scenes | What to ask the platform | How to verify |
|---|---|---|---|
| Full Practice state | Your NP can independently sign your GLP-1 prescription, order labs, and manage dose changes. No physician co-signature exists or is required. | "Who is my prescriber and what's their state license number?" | Your state board of nursing license lookup (free, public, 2 minutes) |
| Reduced Practice state | Your NP holds a documented collaborative agreement with a physician on file. The collaboration may or may not affect your specific visit. | "Who is your collaborating physician for my state, and how does that affect my care?" | State board of nursing for NP + state medical board for the physician |
| Restricted Practice state | A physician is required to supervise, delegate, or co-manage at least one element of NP practice. National platforms maintain a state-specific medical director arrangement. | "Which physician is supervising the NP for my state, and what's that physician's role in my care?" | State board of nursing for NP + state medical board for the physician |
State-Specific Quirks Worth Knowing
Mississippi (2024)
Rule 1.5(F) restricts off-label GLP-1 prescribing solely for weight loss. A 2024 supplemental guidance created a narrow exemption for compounded GLP-1s with documented clinical need or shortage-list status, requiring API and Certificate of Analysis verification.
California
Listed as Restricted, but AB 890 created a '104 NP' license pathway (effective January 1, 2026) where qualified NPs can practice independently after completing a defined supervised-hours period. Implementation continues to roll out through 2026.
Transition-to-practice states
Several FPA states require NPs to complete supervised practice hours before independent practice kicks in. New NPs in these states may still be in their transition period.
Why DEA Telehealth Rules Don't Apply to GLP-1s
Quick answer — the single biggest piece of confusion
Controlled substances (not GLP-1s)
Adderall, Xanax, Vyvanse, opioids, certain testosterone preparations. Regulated under the federal Controlled Substances Act, require DEA registration, subject to Ryan Haight in-person exam requirement. DEA extended pandemic flexibilities through December 31, 2026.
GLP-1s — DEA Schedule: None
Semaglutide, tirzepatide, liraglutide, orforglipron. Not on any DEA schedule. No DEA/Ryan Haight in-person exam requirement. No DEA telehealth-specific rules. State scope, standard of care, FDA labeling, compounding rules, and pharmacy licensing still apply.
NP vs MD vs PA: What Each Credential Actually Means
Quick answer
| Physician (MD or DO) | Nurse Practitioner (NP / APRN) | Physician Assistant (PA) | |
|---|---|---|---|
| Years of training after high school | About 11–15 years (4 college + 4 medical school + 3–7 residency) | About 6–8 years (BSN + MSN or DNP, plus required clinical hours) | About 6–7 years (bachelor's + ~27-month PA program) |
| Training background | Medical school; broad scientific and clinical | Nursing model first, then advanced practice training | Medical model, shorter and faster than physician training |
| Can independently sign a GLP-1 prescription | Yes, in all 50 states | Yes in 28 states + D.C.; with collaborative agreement in other 22 | Almost always under physician supervision/collaboration |
| DEA registration needed for GLP-1s | No (GLP-1s are not controlled) | No | No |
| ABOM board certification in obesity medicine | Eligible | Not eligible (physicians only) | Not eligible |
| OMA Certificate in Obesity Medicine | N/A (physicians use ABOM) | Eligible | Eligible |
| Typical role in GLP-1 telehealth | Medical director, complex cases, hybrid platforms | Primary front-line prescriber on many large platforms | Less common in GLP-1 telehealth than NPs |
Obesity medicine certifications — rarely mentioned
What the Research Says About NP vs Doctor Care Quality
Quick answer
Stanik-Hutt et al. (2013, Journal for Nurse Practitioners)
A systematic review across 37 studies and 11 aggregated outcomes (lipid control, blood pressure, blood glucose, ED visits, hospitalizations, mortality, satisfaction, functional status). Outcomes for NPs compared with physicians were comparable or better across all 11.
Liu et al. (Health Services Research, VA cohort)
Study using Veterans Affairs data of more than 800,000 VA primary care patients found similar clinical outcomes and lower utilization at comparable cost when patients were reassigned to NPs after their physician PCP left practice.
Smith et al. (2020, Medical Care)
Among VA patients with diabetes, compared utilization and costs by primary care provider type (physician, NP, PA) and found differences in patterns of care.
Harrison et al. (2023, INQUIRY)
Multi-state Medicaid analysis comparing NP-attributed to physician-attributed adult patients in states with pay parity. No significant differences in standard diabetes quality measures.
When You Should Specifically Request a Physician (and When an NP Is Fine)
An NP-Led GLP-1 Telehealth Program Is Reasonable If You're…
- A healthy adult with BMI 30+ (or BMI 27+ with one weight-related condition like high blood pressure, high cholesterol, sleep apnea, or PCOS)
- Not currently taking diabetes medication that affects blood sugar (or only on metformin)
- Without a personal history of pancreatitis, gallbladder disease, or severe GI conditions
- Without a personal or family history of medullary thyroid cancer or MEN2
- Not pregnant, breastfeeding, or planning pregnancy soon
- Willing to follow the prescribed labs and follow-up cadence
- Able to clearly identify your prescriber and confirm their state license
Request a Physician (or PCP-Coordinated Care) If You Have…
From the FDA labels for Wegovy, Zepbound, and Foundayo (DailyMed, May 2026):
Type 2 diabetes on insulin, sulfonylureas, or meglitinides
Adding a GLP-1 can drop blood sugar; this needs careful coordination
Diabetic retinopathy
Rapid blood-sugar improvement can temporarily worsen retinopathy
History of pancreatitis
Pancreatitis is a known risk on GLP-1 labels; prior history matters
Gallbladder disease history
Gallbladder problems are more common in patients losing weight rapidly
Severe GI disease or gastroparesis
GLP-1s slow gastric emptying; this can be dangerous in pre-existing gastroparesis
Kidney disease
Dehydration from GLP-1 nausea/vomiting can worsen kidney function
Planned pregnancy
GLP-1 pregnancy guidance is medication-specific; Foundayo specifically may reduce the effectiveness of oral contraceptives (DailyMed Foundayo label)
Personal or family history of medullary thyroid carcinoma (MTC) or MEN2
Boxed-warning contraindication on Wegovy, Zepbound, and Foundayo
Prior severe side effects on a different GLP-1
Needs careful evaluation, not a new shipment
Complex cardiovascular, liver, or sleep apnea disease
Specialty care uses the right GLP-1 for the right indication — Wegovy for CVD risk, Zepbound for OSA, Wegovy for noncirrhotic MASH
Use Your PCP, Not Telehealth, If…
- You're already established with a primary care doctor or endocrinologist who'll prescribe and monitor
- You want insurance to pay for the medication and you need someone to handle prior authorization properly
- You take five or more chronic medications
- You have a complicated medical history that doesn't fit cleanly in an intake form
FDA-Approved vs Compounded: The Safety Question That Matters More Than Credential
Quick answer
If we ranked safety variables in a GLP-1 telehealth decision:
Medication source
FDA-approved vs compounded, named pharmacy, licensed in your state
Screening before prescribing
Contraindication check, medication review, labs
Prescriber's state license and authorization
Verifiable on a state board lookup
Follow-up structure
Real cadence, real responsiveness, real escalation
Prescriber's obesity-medicine experience
ABOM or OMA certificate signals
Prescriber's credential
MD / DO / NP / PA
Marketing Phrases to Translate Before Paying
| Phrase you'll see in ads | What it might mean | What FDA has warned about | What to ask before paying |
|---|---|---|---|
| "Same active ingredient as Ozempic/Wegovy" | The product contains a semaglutide variant — possibly a salt form, possibly an unapproved isomer | FDA has warned about salt forms and unapproved variants being marketed as equivalent | "Is this the same molecule as the FDA-approved drug, or a salt or variant? What's the exact active ingredient name?" |
| "Pharmacy-compounded" | A compounding pharmacy mixed the medication; could be 503A or 503B | FDA has warned about fraudulent compounding pharmacies and labels with false information | "What pharmacy specifically? Are they 503A or 503B? Are they licensed in my state?" |
| "Clinically proven" or "Clinical-grade" | Not a regulated term; could mean anything | FDA has warned about misleading marketing implying compounded products have undergone FDA review | "Is this drug FDA-approved? If not, what evidence supports the formulation specifically?" |
| "Custom GLP-1" or "Personalized GLP-1" | Often means the same compounded product with a custom label | FDA's narrower compounding policy requires a documented patient-specific need | "What's the patient-specific clinical reason this is compounded for me instead of an FDA-approved product?" |
| "Brand-name alternative" | Compounded product positioned as equivalent | Compounded drugs are not FDA-approved generics or substitutes | "Is the manufacturer self-pay program (NovoCare for Wegovy, LillyDirect for Zepbound/Foundayo) available to me, and how does the cost compare?" |
| "FDA-registered pharmacy" | The pharmacy is registered, not that the drug is FDA-approved | Registration is not the same as drug approval — many ads conflate them | "I understand the pharmacy is registered. Is the medication itself FDA-approved?" |
How NP and Doctor GLP-1 Telehealth Visits Actually Differ in Real Life
Quick answer
How does the evaluation happen?
Synchronous video visit
Clinician on camera, you on camera, real conversation. Generally best for first visit and complex history.
Synchronous phone visit
Voice only — better than async for nuanced history, worse than video.
Asynchronous form review
You fill a questionnaire, a clinician reviews and writes. Convenient but can hide issues that come up in conversation.
Hybrid
Async intake plus video visit on request. Good for routine refills, better for complex cases.
Will I see the same clinician each visit?
Dedicated clinician
Same NP or doctor across visits. Continuity matters more than most people realize.
Care team
Multiple clinicians cover your messages. Better than random rotation.
Random rotation
Whoever's online when you message — they're reading your chart for the first time each visit.
How fast do they respond when I have a problem?
24/7 messaging with clinician triage
Strongest — especially relevant for GLP-1 side effects like nausea, vomiting, abdominal pain.
Business-hours-only with same-day SLA
Adequate for stable patients.
No SLA, no clinician message review
Risky for GLP-1 patients who may need urgent guidance.
What labs do they require, and when?
Before prescribing, results reviewed
Strongest.
Recent labs accepted (within 60–90 days from PCP)
Fine for many patients.
At any point after starting, or "as clinically indicated"
Depends entirely on the clinician.
No lab plan and no explanation
A red flag for most patients.
Should I Use Telehealth or My Primary Care Doctor for GLP-1?
Quick answer
Start with your PCP if…
- You already see them and have your medical history with them
- They prescribe obesity medications routinely
- You have insurance that may cover Wegovy or Zepbound and you need prior authorization support
- You have multiple chronic conditions needing coordinated care
- You're already on diabetes medications
Consider telehealth if…
- Your PCP refused and won't reconsider after a clear conversation
- Your PCP isn't available for the next 2–3 months
- Your PCP doesn't offer obesity medication management at all
- You want a structured weight-management program
- You're paying cash either way and the telehealth path is cheaper or faster
If Your Doctor Refused to Prescribe a GLP-1, Before You Switch…
Medical risk
They think your history makes it unsafe — worth taking seriously. Get a second opinion from obesity medicine or endocrinology before going to a low-touch telehealth program.
Insurance/coverage issue
Your plan won't cover it without specific documentation — telehealth PA support may help.
Lack of comfort or training
They don't routinely prescribe obesity meds — telehealth can be a reasonable workaround.
Clinic policy
Some health systems require referral to an obesity medicine clinic.
Supply/shortage concerns
Less common now that semaglutide and tirzepatide are off the FDA shortage list.
If You Go Telehealth, Send Your PCP This List
After your first telehealth GLP-1 prescription, send your PCP:
- The medication name and dose
- The prescriber's name and credential
- The pharmacy filling it
- Your baseline labs (and a copy of the results)
- The titration schedule
- Any side effects you've had
- Your weight and blood pressure trend
- The telehealth program's follow-up schedule
How Much Does GLP-1 Telehealth Cost — Does NP vs Doctor Change What You Pay?
Quick answer
| Cost bucket | Questions to ask |
|---|---|
| First visit / consultation fee | One-time or recurring? |
| Monthly platform / membership fee | Required ongoing? |
| Medication cost | Included in membership, or separate? FDA-approved or compounded? |
| Manufacturer self-pay program | Is NovoCare (Wegovy) or LillyDirect (Zepbound/Foundayo) available to me, and how does the cost compare? |
| Labs | Included, insurance-billed, or cash pay? |
| Insurance prior authorization support | Will the platform actually fight for coverage? |
| Refills | Required follow-ups before refills? |
| Shipping | Included? Discreet? |
| Cancellation | Easy or contractual? |
How to Verify Any GLP-1 Telehealth Prescriber in 10 Minutes
Quick answer
Get the prescriber's full name and credential
Look on the platform — usually in your account, in the messaging thread once matched, or on the 'Meet our clinicians' page. You're looking for: full legal name + credential (MD, DO, NP, APRN, FNP-BC, PA-C, etc.). If you can't find this: that's a red flag. Pause before paying.
Verify the state license
For MDs and DOs: your state's medical board. For NPs and APRNs: your state's board of nursing. For PAs: usually your state medical board. You're verifying: license is active (not expired, lapsed), license is in your state, no disciplinary actions listed. Save a screenshot of the active license listing with the date visible.
Confirm state authorization for your telehealth visit
Ask directly in your first message: "Are you licensed to treat me and prescribe for me while I am physically located in [my state]?" If they can't or won't answer clearly, that's a red flag.
Verify obesity medicine experience
For physicians: ABOM certification (verifiable at the ABOM diplomate directory). For NPs and PAs: OMA Certificate of Advanced Education in Obesity Medicine (verifiable through the Obesity Medicine Association). Neither is required to prescribe GLP-1s legally. Both are strong signals of deeper training.
Verify the medication source
Ask before payment: Is the medication FDA-approved or compounded? If compounded: what's the exact active ingredient (base or salt form)? What pharmacy fills the prescription? Is it licensed in my state? Is the pharmacy a 503A or 503B facility? A legitimate program will answer all of these clearly.
Verify the screening and follow-up
Ask: What labs do you require before prescribing? What's the dose titration schedule? What's the follow-up cadence? How quickly do you respond to messages? What's your protocol if I have severe nausea, vomiting, abdominal pain, dehydration, or low blood sugar? A program with thoughtful answers is doing the job.
Red Flags That Mean Walk Away
Quick answer
Red flags
- "Get your prescription approved in minutes" without a real evaluation
- Prescriber's name not visible before or after your visit
- No state license verification provided or available
- No real medical history intake (just height/weight/age)
- No medication review (no list of your current prescriptions)
- No screening for major contraindications (thyroid history, pregnancy, pancreatitis)
- Compounded GLP-1 marketed as "same as Wegovy" or "same active ingredient as Ozempic"
- Brand-like product names that hide whether the medication is compounded or FDA-approved
- No pharmacy identity disclosed
- No plan for severe side effects (vomiting, abdominal pain, dehydration, low blood sugar)
- No way to message or call a clinician
- Auto-refills with no clinical check-in
- Refund/cancellation terms hidden or punitive
- Influencer urgency messaging or limited-time scarcity tactics for medical decisions
- Claims that compounded drugs are identical to FDA-approved drugs
Green flags
- Prescriber's name, credential, and license number visible
- State authorization explicitly confirmed for your location
- Real intake form with medical history, medications, contraindications screening
- Video visit available (even if async is the default)
- Labs required or accepted before prescribing — or a clear clinical explanation of why they're not needed
- Clear medication source (FDA-approved or compounded, with pharmacy named)
- Clear titration plan and follow-up cadence
- Clear escalation path for side effects (phone number, urgent messaging)
- Willingness to coordinate with your PCP
- No fake urgency
- Transparent pricing with all-in monthly cost disclosed before payment
What 2026's GLP-1 Changes Mean for Choosing a Prescriber
Quick answer
Compounded GLP-1 prescribing is no longer business as usual
In March 2026, the FDA warned 30 telehealth companies for illegal marketing of compounded GLP-1s. With semaglutide and tirzepatide off the FDA shortage list and FDA tightening guidance on essentially-copy compounding, the regulatory tolerance for compounded versions of these drugs for routine weight loss has narrowed. Ask your prescriber explicitly whether they prescribe FDA-approved or compounded GLP-1s, and listen carefully to the answer.
Oral GLP-1s change the prescribing conversation
FDA approved an oral form of Wegovy (semaglutide) in December 2025. Foundayo (orforglipron) followed on April 1, 2026 — a once-daily pill that can be taken with or without food and without water restrictions, unlike oral Wegovy which must be taken on an empty stomach with no more than four ounces of water.
A prescriber managing your GLP-1 in 2026 needs to be conversant in: whether oral or injectable is right for you, dosing transitions if you switch, and Foundayo's oral contraceptive interaction — its label notes that it may reduce the effectiveness of oral contraceptives and recommends non-oral or barrier contraception for a defined period after initiation and each dose escalation. If your telehealth prescriber doesn't seem familiar with these recent approvals, that's worth noticing.
Manufacturer self-pay has changed the cost equation
Novo Nordisk's NovoCare program and Eli Lilly's LillyDirect have rolled out self-pay options for Wegovy, Zepbound, and Foundayo. Foundayo launched with publicized pricing starting at $149/month for the lowest dose (per Lilly). Verify current self-pay pricing on each manufacturer's site before defaulting to compounded — pricing has shifted multiple times in 2025–2026.
Cardiovascular, OSA, and MASH indications now matter for prescriber choice
Wegovy is FDA-approved for cardiovascular risk reduction in adults with established CVD and obesity/overweight, and for noncirrhotic MASH with moderate to advanced liver fibrosis (accelerated approval). Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. For patients with these conditions, the right prescriber understands which GLP-1 to choose for which indication and how to document it for insurance — where physician or specialist-connected care has a real advantage.
How We Built This Guide
We compared GLP-1 nurse practitioner vs doctor telehealth using legal authorization, clinical risk, medication-source transparency, monitoring quality, cost, and follow-up — not credential stereotypes. All sources are dated .
Update cadence: State practice authority — re-verified quarterly against AANP map. FDA approvals and warning letters — monthly during 2026. DEA telehealth rule status — quarterly (next major checkpoint December 31, 2026). Peer-reviewed evidence — annually. If something on this page is wrong or has gone stale, write us — we'd rather fix it than publish bad information.
Related guides
- Who can prescribe GLP-1 medications online — full role-by-role guide
- GLP-1 telehealth safety checklist — 15-point vetting guide
- How to verify your GLP-1 prescriber's license — 50-state board lookup guide
- Foundayo vs Zepbound — pill vs shot comparison for 2026
- Best GLP-1 pill for women — Foundayo vs Wegovy pill
- Switching from MEDVi to Ro — 7-step plan for FDA-approved medication
- GLP-1 provider reviews — compare FDA-approved telehealth programs
Frequently Asked Questions
Ready to find a GLP-1 provider that passes every check?
Ro uses board-licensed clinicians, prescribes FDA-approved GLP-1 medications, discloses your prescriber's name, and includes free insurance coverage checking and prior-authorization support.
Start with Ro — $39 First MonthThis article is general health information. It is not personal medical advice, a diagnosis, or a treatment recommendation. Talk to a licensed clinician about your specific situation before starting, stopping, or changing any medication.